The synaptic hypothesis of schizophrenia has been highly influential. However, new
approaches mean there has been a step-change in the evidence available, and some tenets …

Abstract Treatment-resistant schizophrenia (TRS), the persistence of positive symptoms
despite≥ 2 trials of adequate dose and duration of antipsychotic medication with …

The American Psychiatric Association Practice Guideline for the Treatment of Patients With
Schizophrenia seeks to reduce these substantial psychosocial and public health …

Clinical practice guidelines (CPGs) translate evidence into recommendations to improve
patient care and outcomes. To provide an overview of schizophrenia CPGs, we conducted a …

Background The degree of efficacy, safety, quality, and certainty of meta-analytic evidence of
biological non-pharmacological treatments in mental disorders is unclear. Methods We …

A recent increase in the literature regarding the evidence base for clozapine has made it
increasingly difficult for clinicians to judge “best evidence” for clozapine use. As such, we …

Antipsychotic drugs are the mainstay in the treatment of schizophrenia. However, one-third
of patients do not show adequate improvement in positive symptoms with non-clozapine …

Schizophrenia is the eighth leading cause of disability worldwide in people aged 15–44
years. Before antidopaminergic antipsychotics were introduced in the 1950s, no effective …

Abstract Using Richardson and Davidson's model and the sciences of pharmacokinetics and
clinical pharmacopsychology, this article reviewed the:(1) poor life expectancy associated …

Introduction Patients with schizophrenia have an elevated mortality risk compared to the
general population, with cardiovascular-related deaths being the leading cause. The role of …